41 results on '"Umar, Abdullahi Bello"'
Search Results
2. Investigation of Novel Imidazole Analogues with Terminal Sulphonamides as Potential V600E-BRAF Inhibitors Through Computational Approaches
3. Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling
4. Molecular docking studies of some benzoxazole and benzothiazole derivatives as VEGFR-2 target inhibitors: In silico design, MD simulation, pharmacokinetics and DFT studies
5. QSAR application of natural therapeutics inhibitors against Alzheimer's disease through in-silico virtual-screening, docking-simulation, molecular dynamics, and pharmacokinetic prediction analysis
6. 2D and 3D-QSAR Modeling of 1H‑Pyrazole Derivatives as EGFR Inhibitors: Molecular Docking, and Pharmacokinetic Profiling
7. Structure Based Design of Some Novel 3-Methylquinoxaline Derivatives Through Molecular Docking and Pharmacokinetics Studies as Novel VEGFR-2 Inhibitors
8. Pharmacokinetic profiling of quinazoline-4(3H)-one analogs as EGFR inhibitors: 3D-QSAR modeling, molecular docking studies and the design of therapeutic agents
9. Computational design of quinoxaline molecules as VEGFR-2 inhibitors: QSAR modelling, pharmacokinetics, molecular docking, and dynamics simulation studies
10. In-silico design of some pyrazolopyridine analogs as breast cancer inhibitors: QSAR modeling, molecular docking, MD simulation, and pharmacological features profiling
11. In-silico profiling, design, molecular docking computation, and drug kinetic model evaluation of novel curcumin derivatives as potential anticancer agents
12. Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents
13. Salicylic acid derivatives as potential α-glucosidase inhibitors: drug design, molecular docking and pharmacokinetic studies
14. In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line
15. In-silico Investigation by Molecular Docking, DFT and Pharmacokinetic Studies of Some Synthesized 1,8-Naphthyridine Derivatives as Prospective Anti-Breast Cancer Agents
16. QSAR application of natural therapeutics inhibitors against Alzheimer's disease through in-silico virtual-screening, docking-simulation, molecular dynamics, and pharmacokinetic prediction analysis
17. Multi-protein targeting potential of some urea, thiourea, and selenourea derivatives of diselenides in leishmaniasis: molecular docking screening, oral bioavailability analysis, ADMET profiling, and molecular dynamics simulation
18. Molecular Docking Strategy to Design Novel V600E-BRAF Kinase Inhibitors with Prediction of Their Drug-Likeness and Pharmacokinetics ADMET Properties
19. QSAR and Docking Studies on Some Potential Anti-Cancer Agents to Predict their Effect on M14 Melanoma Cell Line
20. Ligand-based drug design and molecular docking simulation studies of some novel anticancer compounds on MALME-3M melanoma cell line
21. Chemo-informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anti-cancer agents
22. QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2
23. Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors
24. Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET properties
25. In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions
26. Investigation of Novel Imidazole Analogues with Terminal Sulphonamides as Potential V600E-BRAFInhibitors Through Computational Approaches
27. Theoretical investigation and design of some indole derivatives as potent β-glucuronidase inhibitors
28. Design of potential anti-melanoma agents against SK-MEL-5 cell line using QSAR modeling and molecular docking methods
29. QSAR, molecular docking, and design of novel 4-(N,N-diarylmethyl amines) Furan-2(5H)-one derivatives as insecticides against Aphis craccivora
30. L-Arginine Grafted Chitosan as Corrosion Inhibitor for Mild Steel Protection
31. Molecular modeling strategy to design novel anticancer agents against UACC-62 and UACC-257 melanoma cell lines
32. Drug Design, Molecular Docking and Dynamics Studies on the Interaction of Voxelotor, L- Glutamine and Hydroxy Urea with Human Carbonmonoxy Hemoglobin S
33. Modelling PIP4K2A inhibitory activity of 1,7-naphthyridine analogues using machine learning and molecular docking studies
34. Characterization of the Structural and Optical Properties of Copper Oxide for Use in Solar Cells Using Screen Printing Method
35. Ligand-based drug design, molecular docking and pharmacokinetic studies of some series of 1,4 - dihydropyridines derivatives as human intestinal maltase-glucoamylase inhibitor
36. Molecular Docking , ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors
37. Thermal Cycle Testing of a few Selected Inorganic Salts as Latent Heat Storage Materials for High- Temperature Thermal Storage
38. In silico Studies of some potential anti-cancer agents on M19-MEL cell line
39. Molecular Docking Strategy to Design Novel V600E-BRAF Kinase Inhibitors with Prediction of Their Drug-Likeness and Pharmacokinetics ADMET Properties
40. Molecular Modelling, Docking and Pharmacokinetic Studies of N-Arylidenequinoline-3-Carbohydrazides Analogs as Novel β-Glucuronidase Inhibitors
41. In silico Studies of some potential anti-cancer agents on M19-MEL cell line
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.